瑞珍斯生物

关于 Regenxbio

REGENXBIO, Inc. is a clinical-stage biotechnology company, which 从事 the 开发, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV 技术 平台, which 包括 exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was 成立 by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is 总部位于 in Rockville, MD.

成立时间

2008

首席执行官

Mr. Curran Simpson

员工人数

371

总部地址

Rockville, Maryland, United States of America

财年结束日

12-31

官方网站

regenxbio.com

公司概况

交易所

US

股票代码

RGNX

市值排名

#3748

上市日期

2015-09-17

市值

457.14M

流通市值

396.32M

总股数

66.01M

流通股数

57.23M

行业与主题板块

浏览全部行业与主题板块